Share News: Small company's stock suddenly rocketed, FIIs bought not one but millions of shares, price rose 40% in 3 months:After the market opened, there was strong buying, and the stock quickly climbed to ₹244.

News Topical, Digital Desk : Shares of this small pharmaceutical company have seen a strong rally. On Tuesday, the stock jumped 10% to an all-time high of ₹244. Strong buying, record foreign investment (FII) stakes, and the company's global business model have fueled the stock's surge. Over the past one month, one year, and three years, the stock has delivered impressive returns, enriching investors. The company's strong exports and specialized product portfolio are its biggest strengths.

Shares of Bliss GVS Pharma, a leading pharmaceutical company, have seen a significant surge. The stock opened at ₹222, a slight increase from its previous close of ₹221.97.
However, after the market opened, there was heavy buying, and the stock quickly climbed to ₹244. This level is the company's all-time high. Thus, the stock registered a massive gain of nearly 10% in a single day.

Investors became rich due to the excellent returns. Bliss GVS Pharma's stock has consistently delivered excellent returns to investors. In the past month alone, the stock has risen nearly 40%. In the past year, the stock has delivered a strong 90% return. Looking at the long term, the stock has risen by nearly 200% in the past three years. This means that those who invested for the long term have benefited significantly.

Record FII participation, increased confidence Foreign investors' confidence in this stock is steadily increasing. In September 2025, FIIs' stake in the company was 13.27%, which increased to 14.54% by December 2025. This is the highest foreign holding in the company to date. This clearly indicates that large foreign investors are very positive about the company's future and see long-term growth. Meanwhile, promoters' stake in the company is 35.36%, reflecting the promoters' strong confidence in the company's business.
What does the company do?
Bliss GVS Pharma is a pharmaceutical company, which is among the world's leading companies in the suppositories and pessaries segment. Apart from this, the company manufactures, markets and exports a variety of medicines.

The company has a strong portfolio of more than 150 branded formulations. This includes medicines like anti-malarial, anti-fungal, anti-bacterial, anti-inflammatory, contraceptive and anti-diabetic. The company manufactures a variety of products like suppositories, pessaries, capsules, tablets, syrups and injections.

Strong hold in the global market
The business of Bliss GVS Pharma is not limited to India only. The company exports its products to more than 60 countries. Especially in Africa, the company has a strong hold in the anti-malarial segment. Brands like Lonart, P-Alaxin and Funbact are very popular there.

Strong Manufacturing and Growth Plan
The company has five modern manufacturing plants that meet international standards such as USFDA, EU-GMP, WHO, TGA, and Health Canada. Furthermore, the company offers CMO and CDMO services. The company's focus is on developing affordable, high-quality generic medicines and strengthening research and development.

What is the main reason for the rally?
The biggest reason for the stock's rally is the company's robust business model, increasing foreign investor participation, and strong presence in the global market. Investors expect both the company's revenue and profits to remain strong in the future.

Overall... Bliss GVS Pharma stock is currently in a strong trend, and the company's fundamentals, global exports, and increasing FII participation are making it attractive to investors.